Optimal duration of levetiracetam prophylaxis following supratentorial tumor resection: a multi-study analysis.
Kenan Kıbıcı, Nur Ozturk, Nilay Aksoy
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis compared short-course (≤ 9 days) with extended-course (> 9 days) levetiracetam prophylaxis in seizure-naïve patients after supratentorial tumor resection. Eight studies comprising nine cohorts (N = 385) were included. The pooled seizure incidence with short-course prophylaxis was 2.4% (95% CI: 1.1%-4.6%), below the cited 12% historical baseline. Extended-course cohorts had higher, variable seizure rates, and the analysis found no clear additional protection against late-onset seizures; extended treatment was associated with neuropsychiatric toxicity and attrition.
Key findings
- Short-course levetiracetam (≤ 9 days) was associated with a pooled seizure incidence of 2.4% (95% CI: 1.1%-4.6%).
- Extended-course cohorts had seizure rates up to 34.7%, statistically indistinguishable from the 20% untreated late-onset benchmark.
- Treatment duration and tumor type were significant moderators of seizure outcomes (p < 0.05); age, gender, and levetiracetam dosage were not.
- The review described a day-14 shift toward severe neuropsychiatric toxicity with extended therapy, contributing to high attrition.
Why it matters
Seizure prophylaxis after tumor resection must balance potential prevention against medication harms. These pooled findings suggest that longer levetiracetam exposure may not provide added protection against late-onset seizures, while neuropsychiatric toxicity can limit tolerability. The results highlight the importance of considering duration and adverse effects when evaluating prophylaxis, while recognizing that the evidence is not definitive.
What to keep in mind
The analysis pooled eight studies across nine cohorts, and the authors state that prospective controlled trials are needed to establish definitive guidelines.